Murphy & Mullick Capital Management Corp Catalyst Pharmaceuticals, Inc. Transaction History
Murphy & Mullick Capital Management Corp
- $109 Billion
- Q4 2024
A detailed history of Murphy & Mullick Capital Management Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 1,150 shares of CPRX stock, worth $25,966. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,150Holding current value
$25,966% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
342Shares Held
98.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$422 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$190 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$141 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$128 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$68.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.32B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...